A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression

Zhen Tang,Jing Hu,Xu-Chang Li,Wei Wang,Han-Yue Zhang,Yu-Yao Guo,Xin Shuai,Qian Chu,Conghua Xie,Dandan Lin,Bo Zhong
DOI: https://doi.org/10.1016/j.devcel.2024.10.010
IF: 13.417
2024-11-11
Developmental Cell
Abstract:Summary Neutrophils in the tumor microenvironment (TME) are heterogeneous populations associated with cancer prognosis and immunotherapy. However, the plasticity and function of heterogeneous neutrophils in the TME of non-small-cell lung cancer (NSCLC) remain unclear. Here, we show that neutrophils produce high levels of interleukin (IL)-8, which induce the differentiation of CD74 high SiglecF low neutrophils and suppress the generation of CD74 low SiglecF high neutrophils in the TME of IL-8-humanized NSCLC mice. The CD74 high SiglecF low neutrophils boost anti-tumor T cell responses via antigen cross-presentation. Deleting CD74 in IL-8-humanized neutrophils impairs T cell activation and exacerbates NSCLC progression, whereas a CD74 agonist enhances T cell activation and the efficacy of anti-programmed cell death 1 (PD-1) or osimertinib therapies. Additionally, the CD74 high CD63 low neutrophils in the TME and peripheral blood of advanced NSCLC patients phenocopy the CD74 high SiglecF low neutrophils in the TME of NSCLC mice and correlate well with the responsiveness to anti-PD-1 plus chemotherapies. These findings demonstrate an IL-8-CD74 high neutrophil axis that promotes anti-tumor immunity in NSCLC.
cell biology,developmental biology
What problem does this paper attempt to address?